


GAU 1643



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)  
Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/917,974
	Filing Date	July 30, 2001
	First Named Inventor	Ligensa et al
	Group Art Unit	1643
	Examiner Name	
Total Number of Pages in This Submission	7	Confirmation Number

RECEIVED

SEP 06 2001

TECH CENTER 600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Additional Enclosure(s) (please identify below): <div style="border: 1px solid black; height: 50px; width: 100%;"></div>
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	F. Aaron Dubberley
Signature	<i>F. Aaron Dubberley</i>
Date	August 30, 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail on the date shown below in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231:			
Typed or printed name	F. Aaron Dubberley	Date	August 30, 2001
Signature	<i>F. Aaron Dubberley</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



#4  
RECEIVED

SEP 06 2001

TECH CENTER 1600/2900

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Ligensa et al

Group: 1643

Serial No. 09/917,974, filed July 30, 2001

Examiner:

For: IGF-1 RECEPTOR INTERACTING PROTEINS

**INFORMATION DISCLOSURE STATEMENT**

Nutley, New Jersey 07110  
August 30, 2001

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents listed on Form PTO-1449 are not being submitted because each has been made of record in the parent application, Serial No. 09/453,195, filed December 2, 1999, now allowed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "F. Aaron Dubberley", written over a horizontal line.

*Agent for Applicant(s)*

F. Aaron Dubberley

(Reg. No. 41001)

340 Kingsland Street

Nutley, New Jersey 07110

Telephone: (973) 235-4387

Telefax: (973) 235-2363

113471



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)


Complete if Known

Application Number	09/917,974
Filing Date	July 30, 2001
First Name Inventor	Ligensa, Tanja
Group Art Unit	1643
Examiner Name	
Attorney Docket Number	9515

RECEIVED

SEP 06 2001

TECH CENTER 1600/2900



**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C1	Rousset et al., <i>Oncogene</i> , Vol. 16, pp. 643-654 (1998)	
	C2	De Vries et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp. 12340-12345 (1998)	
	C3	No. XP-002102461, Database EMBL ID AF 032120, Bunn et al., "Cloning and Characterization of GLUT1CBP, a Novel PDZ domain-containing Protein that Binds Specifically to the GLUT1 Transporter C-terminus" (1998)	
	C4	No. XP-002102452, Abstract of Bunn et al., "Identification and Characterization of a Novel Glucose Transporter Binding Protein" (1997)	
	C5	No. XP-002102462, Database EMBL ID AF061262 (1998)	
	C6	Lamothe et al., <i>Gene</i> , Vol. 182, pp. 77-80 (1996)	
	C7	Dey et al., <i>Gene</i> , Vol. 209, pp. 175-183 (1998)	
	C8	Baserga, <i>Trends in Biology</i> , Vol. 14, pp. 50-152 (1996)	
	C9	Baserga, <i>Perspective in Cancer Research</i> , Vol. 55, pp. 249-252 (1995)	
	V10	Atschul et al., <i>J. Mol. Biol.</i> , Vol. 215, pp. 403-410 (1990)	
	C11	Atschul et al., <i>Nucleic Acids Res.</i> , vol. 25, pp. 3389-3402 (1997)	
	C12	Bates et al., <i>Br. J. Cancer</i> , Vol. 72, pp. 1189-1193 (1995)	
	C13	Behrens et al., <i>Nature</i> , Vol. 382, pp. 638-642 (1996)	
	C14	Behrens et al., <i>Science</i> , Vol. 280, pp. 596-599 (1998)	
	C15	Burfeind et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 7263-7268 (1996)	
	C16	Büttner et al., <i>Mol. Cell. Biol.</i> , Vol. 11, pp. 3573-3583 (1997)	
	C17	Cabral et al., <i>Nature</i> , Vol. 382, pp. 649-652 (1996)	
	C18	Chomczynski et al., <i>Anal. Biochem.</i> , Vol. 162, pp. 156-159 (1987)	
	C19	Chowdhury et al., <i>Mech. Dev.</i> , Vol. 39, pp. 129-142 (1992)	
	C20	Cooke et al., <i>New Biol.</i> , Vol. 1, pp. 66-74 (1989)	
	C21	Denny et al., <i>Gene</i> , Vol. 106, pp. 221-227 (1991)	
	C22	Dey et al., <i>Mol. Endocrinol.</i> , Vol. 10, pp. 631-641 (1996)	
	C23	Feinberg et al., <i>Anal. Biochem.</i> , Vol. 137, pp. 266-267 (1984)	
	C24	Fields et al., <i>Nature</i> , Vol. 340, pp. 245-246 (1989)	
	C25	Goulding et al., <i>EMBO J.</i> , Vol. 10, pp. 1135-1147 (1991)	
Examiner Signature			DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or abstract is attached.

113472

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		Application Number	09/917,974
		Filing Date	July 30, 2001
		First Name Inventor	Ligensa, Tanja
		Group Art Unit	1643
		Examiner Name	
Sheet	3	Attorney Docket Number	9515

RECEIVED

SEP 06 2001

TECH CENTER 1600/2900


NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C26	Harrington et al., <i>EMBO J.</i> , Vol. 13, pp. 3286-3295 (1994)	
	C27	He, W., et al., <i>J. Biol. Chem.</i> , Vol. 271, pp. 1641-11645 (1996)	
	C28	Kalebic et al., <i>Cancer Research</i> , Vol. 54, pp. 5531-5534 (1994)	
	C29	Kaleko et al., <i>Mol. Cell. Biol.</i> , Vol. 10, pp. 464-473 (1990)	
	C30	Lamothe et al., <i>FEBS Lett.</i> , Vol. 373, pp. 51-55 (1995)	
	C31	Lehmann et al., <i>Nucleic Acids Res.</i> , Vol. 18, pp. 1048 (1990)	
	C32	Margolis et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 8894-8898 (1992)	
	C33	Morrione et al., <i>J. Virol.</i> , Vol. 69, pp. 5300-5303 (1995)	
	C34	Morrione et al., <i>Cancer Research</i> , Vol. 56, pp. 3165-3167 (1996)	
	C35	Needleman et al., <i>J. Biol. Chem.</i> , Vol. 48, pp. 443-453 (1970)	
	C36	Pearson, <i>Methods in Enzymology</i> , Academic Press, San Diego, CA, USA, Vol. 183, pp. 63-68 (1990)	
	C37	Ponting et al., <i>BioEssays</i> , Vol. 19, pp. 469-479 (1997)	
	C38	Prager et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 2181-2185 (1994)	
	C39	Quinn et al., <i>J. Biol. Chem.</i> , Vol. 271, pp. 11477-11483 (1996)	
	C40	Resnicoff et al., <i>Cancer Research</i> , Vol. 54, pp. 2218-2222 (1994)	
	C41	Resnicoff et al., <i>Cancer Research</i> , Vol. 54, pp. 4848-4850 (1994)	
	C42	Resnicoff et al., <i>Cancer Research</i> , Vol. 55, pp. 2463-2469 (1995)	
	C43	Resnicoff et al., <i>Cancer Research</i> , Vol. 55, pp. 3739-3741 (1995)	
	C44	Reidel et al., <i>J. Biochem.</i> , Vol. 122, pp. 1105-1113 (1997)	
	C45	Rocchi et al., <i>Endocrinology</i> , Vol. 137, pp. 4944-4952 (1996)	
	C46	Rogler et al., <i>J. Biol. Chem.</i> , Vol. 269, pp. 13779-13784 (1994)	
	C47	Sell et al., <i>Cancer Research</i> , Vol. 55, pp. 303-305 (1995)	
	C48	Sell et al., <i>Mol. Cell. Biol.</i> , Vol. 14, pp. 3604-3612 (1994)	
	C49	Sell et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 11217-11221 (1993)	
	C50	Singleton et al., <i>Cancer Research</i> , Vol. 56, pp. 4522-4529 (1996)	
	C51	Smith et al., <i>Adv. Appl. Math.</i> , Vol. 2, pp. 482-489 (1981)	
Examiner Signature	DATE CONSIDERED		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or abstract is attached.





~~SEP 06 2001~~

~~TECH CENTER~~ 1600/2900

[illegible]

Examiner  
Signature

DATE  
CONSIDERED

Signature	CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include conv of this form with next communication to applicant.</p>	

1) Unique citation designation number. 2) Applicant is to place a check mark here if English language Translation or abstract is attached.

113472